Genetic susceptibility to severe immune-related adverse events from immune checkpoint inhibitors
Year: 2026
Type: article
Study design: Observational Study
Abstract: The etiology and pathogenesis of immune-related adverse events (irAEs) remain poorly understood. Progress has been limited by the rarity and heterogeneity of severe irAEs, small cohorts, and underrepresentation of Asian populations. The unpredictability of severe irAEs hinders effective pre-treatment risk stratification. We sought to identify germline genetic determinants of severe irAEs in an Asian cohort of cancer patients. We prospectively recruited 505 cancer patients of Asian ancestry treated with immune checkpoint inhibitors (ICIs) across two tertiary institutions in Singapore. Patients experiencing lower-grade irAEs (Grades 1–2) were excluded from the association analysis to enable a direct comparison between severe cases and unaffected controls. Of 330 patients comparing Cases (NCI-CTCAEv5 ≥ Grade 3 IrAE) and Controls (without irAE), a multi-ethnic pharmacogenomic genome-wide association study (GWAS) was performed across more than 18 cancer subtypes. To complement the agnostic GWAS, an exploratory candidate gene analysis was also performed. LINC01192 rs146525069 was identified as a candidate variant associated with severe irAEs (allele frequency 10.91% in Cases vs 0.73% in Controls, P = 3.51 × 10 −8 , OR = 24.81 (6.92–88.92)). Exploratory candidate gene analysis revealed four polymorphic variants in genes linked to inflammatory and autoimmune diseases: TNF rs1800629 ( P = 0.0044; OR = 2.48; 95% CI = 1.36–4.52), PTPN2 rs1893217 ( P = 0.0117; OR = 1.79; 95% CI = 1.15–2.79), PTPN2 rs2542151 ( P = 0.0195; OR = 1.71; 95% CI = 1.10–2.67) and ROBO1 rs162263 ( P = 0.0480; OR = 0.56; 95% CI = 0.30–1.03). This is the first pharmacogenomic study of high-grade irAEs in an Asian population, identifying LINC01192 as a variant associated with severe irAEs. Our findings also highlight shared immune regulatory pathways between irAEs and autoimmune diseases, supporting the development of germline-based risk stratification to personalize ICI therapy.
Source: Cancer Immunology Immunotherapy
Authors: Yiqing Huang, Joseph J. Zhao, Alvin Wong, Sen Hee Tay, Yu Yang Soon, Yvonne Ang, Chris Lixian Tan, Samantha Peiling Yang, Adrian C. L. Kee, Mark D. Muthiah, Kay W. P. Ng, Li-Ling Tan, Jonathan Lee, Manjari Lahiri, May Shuen Tang, Chieh Yang Koo, Amy M. L. Quek, Esther Chan, Eng Soo Yap, Joan Choo, Wei Sheng Edwin Thong, Valencia Lim, Mamta Ruparel, Yi Da, Margaret Li Peng Teng, Lingzhi Wang, Thuya Win Lwin, Soo Chin Lee, Anand D. Jeyasekharan, Ming Yee Sim, Lavina D. Bharwani, Boon Cher Goh, Li Ren Kong, Folefac Aminkeng, Ross A. Soo
Institutions: National University of Singapore, National University Cancer Institute, Singapore, National University Hospital, National University Health System, National University Heart Centre Singapore, National Heart Centre Singapore, Cancer Science Institute of Singapore, Nanyang Technological University, Tan Tock Seng Hospital, Medical College of Wisconsin
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,590
OpenAlex ID: W7235875616
